Diabetes drug: Sanofi unveils Soliqua in India
Soliqua is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.;
Mumbai: Sanofi India Limited has launched its’ new diabetes drug Soliqua after having received the marketing authorization from the Central Drugs Standard Control Organization (CDSCO) earlier last year. Soliqua is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
Living with type 2 diabetes could get complicated and burdensome. A large category of patients on multiple medications have to deal with weight gain, hypoglycemia and multiple injection pricks, even as they struggle to keep their blood sugar under control. The need of the hour is to help them reach and maintain optimal glycemic (blood sugar) control, keeping such worries at bay. Soliqua simplifies these complexities by offering patients a sustained blood-sugar control, all day, in a simple, once-daily injection that can seamlessly fit into their lifestyle and help them break through the complexity of their diabetes management.
Soliqua is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.
"This global innovation is now accessible at a nominal therapy cost of INR 1850 per pen, enabling wider access to patients living with type 2 diabetes mellitus," the Company stated.
Read also: Sanofi new polio vaccine gets nod in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.